109924-24-5

Basic information

• Product Name: tert-butyl-(1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
• Synonyms: tert-butyl-(1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
• CAS NO: 109924-24-5
• Molecular Weight: 303.361
• Mol File: 109924-24-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: tert-butyl-(1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-(1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate(109924-24-5)
• EPA Substance Registry System: tert-butyl-(1-((cyanomethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate(109924-24-5)

Safety Data

• Hazardous Substances Data: 109924-24-5(Hazardous Substances Data)

Upstream product

• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 151-63-3 cyanomethylamine sulfate 
• 518314-53-9 2-(N-(tert-butoxycarbonyl)amino)-2-benzylpropanedioic diethyl ester 
• 102831-44-7 diethyl tert-butoxycarbonylaminomalonate 
• 100-39-0 benzyl bromide 
• 6011-14-9 2-aminoacetonitrile hydrochloride 
• 3674-06-4 Boc-Phe-ONSu 

Downstream Products

• 42428-77-3 acetonitrile 
• 109924-32-5 N-(tert-Butoxycarbonyl)-L-phenylalanyl-glycin-imidthiosaeure-S-ethylester 
• 191033-48-4 N-Cbz-(S)-phenylalanine-(S)-cyclopropanecarboxylic acid methyl ester 
• 191033-34-8 benzyl (S)-(1-((1-cyanocyclopropyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 

Relevant articles and documents

Influence of azide incorporation on binding affinity by small papain inhibitors

In order to develop affinity-based biosensor platforms, appropriate ligands with a functional handle for immobilization onto a biosensor surface are required. To this end, a library of papain inhibitors was designed and synthesized, containing different a

Nitrile-containing enzyme inhibitors and ruthenium complexes thereof

The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS AND THEIR USE

The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors.